Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Group Of Employees Being Fired By Their Company.

Layoffs

Lyell Cuts 73 Employees as Part of LA Site Closure

After moving the manufacturing of a CAR T drug that was part of its ImmPACT Bio acquisition to Washington, Lyell Immunopharma is closing its Los Angeles manufacturing facility, eliminating dozens of jobs there.

April 7, 2025

1 min read

Angela Gabriel

Woman checking her weight on a measuring device after dieting

Obesity

Rhythm Drug Leads to Reduced BMI in Rare Obesity Indication

Stifel analysts were bullish on the data, which showed a 16.5% drop in body-mass index among patients with damage to the hypothalamus taking Rhythm Pharmaceuticals’ Imcivree.

April 7, 2025

2 min read

Dan Samorodnitsky

Modern collage with halftone hands give and take money. Financial transaction. Money investments. Cash payment. Pay for something

Neuroscience

GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

April 7, 2025

2 min read

Tristan Manalac

President Donald Trump delivers remarks at the Department of Justice in Washington, D.C., Friday, March 14, 2025. (Official White House Photo by Joyce N. Boghosian)

Obesity

Trump Scraps Biden’s Proposed Medicare Coverage for Obesity Drugs

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

April 7, 2025

2 min read

Tristan Manalac

Robert F Kennedy Jr speaking at the White House

Government

Kennedy Changes Tune on MMR Vaccine as Second Child Dies of Measles

Kennedy, a long-time opponent of vaccines, stated that the MMR vaccine is “the most effective way” to combat the measles outbreak, which has already claimed the lives of two children in the U.S.

April 7, 2025

2 min read

Tristan Manalac

Tired girl, exhausted of study vector illustration. Cartoon young woman sleeping next to books, sleepy girl student character sitting at table, studying hard before exam at home interior background

Neuroscience

Centessa’s Narcolepsy Drug Shows ‘Compelling’ Effect in Early Study

Analysts at BMO Capital Markets said Centessa’s orexin receptor agonist has “best-in-class” potential for narcolepsy, putting the company in a strong position in the $15 billion market.

April 7, 2025

2 min read

Tristan Manalac

Washington DC â April 3, 2019: Cherry blossom festival with Washington memorial around the tidal basin

IN PARTNERSHIP WITH DIA

Beyond Neutrality: How Nonprofit Organizations Drive Healthcare Innovation and Collaboration

Health-focused nonprofits like the Drug Information Association (DIA) serve as crucial bridge-builders in the healthcare ecosystem during a time of uncertainty.

April 7, 2025

7 min read

BioSpace Insights

Legal

Lilly’s Fight to Stop Zepbound Knockoffs Leads to Lawsuit Against Indianapolis Spa

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and repackaging them into separate doses.

April 7, 2025

4 min read

Annalee Armstrong